No insider purchase over the last 90 days. The latest was filed 23 Sept 2024.
This page follows insider dealings at Clinica Baviera, S.A. as filed with CNMV, a company from the Health Care sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Clinica Baviera, S.A. logged 7 filings by 2 insiders.
No insider bought on the market over the period, while 2 insiders filed 6 sales totalling €90k. Luis Gravalos Soria filed the largest sale, €49k, on 15 October 2026, which represents 0.0056% of the company's market value.
For context, the typical company on the same exchange (median of 102 companies) published 7 filings over the same period, against 7 filings here. Looking back to 2021, when coverage begins, insiders filed 24 purchases and 20 sales.
Between a trade and the moment it shows up on CNMV, the median delay is 3 days. For comparison, MAR article 19 gives managers three business days to notify a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from CNMV disclosures alone and does not predict where the share price will go.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 47 declarations
Clinica Baviera, S.A. is a company operating in the healthcare and pharmaceutical sector, listed on the XMAD market. It focuses on ophthalmological services and vision treatments.
Purchases our model currently ranks for the recommendations list.
All recommendationsInsider filings
Over the last 90 days, 3 filings published between 31 August and 15 October 2026: 2 sales for €69k. 1 other filing (not open-market purchases or sales: grants, options, plans, sale notices, block transfers). Largest amounts: LUIS GRAVALOS SORIA (CEO), sales of €69k.
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 16 October 2026 (UTC)